Structural homology between 11 beta-hydroxysteroid dehydrogenase and Mycobacterium tuberculosis Inh-A enzyme: Dehydroepiandrosterone as a potential co-adjuvant treatment in diabetes-tuberculosis comorbidity

Front Endocrinol (Lausanne). 2023 Jan 9:13:1055430. doi: 10.3389/fendo.2022.1055430. eCollection 2022.

Abstract

Metabolic syndrome is considered the precursor of type 2 diabetes mellitus. Tuberculosis is a leading infection that constitutes a global threat remaining a major cause of morbi-mortality in developing countries. People with type 2 diabetes mellitus are more likely to suffer from infection with Mycobacterium tuberculosis. For both type 2 diabetes mellitus and tuberculosis, there is pulmonary production of anti-inflammatory glucocorticoids mediated by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The adrenal hormone dehydroepiandrosterone (DHEA) counteracts the glucocorticoid effects of cytokine production due to the inhibition of 11β-HSD1. Late advanced tuberculosis has been associated with the suppression of the Th1 response, evidenced by a high ratio of cortisol/DHEA. In a murine model of metabolic syndrome, we determined whether DHEA treatment modifies the pro-inflammatory cytokines due to the inhibition of the 11β-HSD1 expression. Since macrophages express 11β-HSD1, our second goal was incubating them with DHEA and Mycobacterium tuberculosis to show that the microbicide effect was increased by DHEA. Enoyl-acyl carrier protein reductase (InhA) is an essential enzyme of Mycobacterium tuberculosis involved in the mycolic acid synthesis. Because 11β-HSD1 and InhA are members of a short-chain dehydrogenase/reductase family of enzymes, we hypothesize that DHEA could be an antagonist of InhA. Our results demonstrate that DHEA has a direct microbicide effect against Mycobacterium tuberculosis; this effect was supported by in silico docking analysis and the molecular dynamic simulation studies between DHEA and InhA. Thus, DHEA increases the production of pro-inflammatory cytokines in the lung, inactivates GC by 11β-HSD1, and inhibits mycobacterial InhA. The multiple functions of DHEA suggest that this hormone or its synthetic analogs could be an efficient co-adjuvant for tuberculosis treatment.

Keywords: 11β-hydroxysteroid dehydrogenase; InhA; dehydroepiandrosterone; glucocorticoid; inflammation; lung; tuberculosis; type 2 diabetes mellitus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 11-beta-Hydroxysteroid Dehydrogenase Type 1 / metabolism
  • Animals
  • Anti-Infective Agents*
  • Comorbidity
  • Cytokines
  • Dehydroepiandrosterone / therapeutic use
  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / drug therapy
  • Glucocorticoids / metabolism
  • Humans
  • Metabolic Syndrome*
  • Mice
  • Mycobacterium tuberculosis*
  • Tuberculosis* / drug therapy

Substances

  • 11-beta-Hydroxysteroid Dehydrogenase Type 1
  • Dehydroepiandrosterone
  • Glucocorticoids
  • Cytokines
  • Anti-Infective Agents

Grants and funding

This work was supported by the Fellowship Member Program to IH-B and YS-P from the UNU-BIOLAC Program for Biotechnology in Latin America and the Caribbean (ID 609UU-0249). Grants from the Scientific and Technical National Research Council (CONICET) to Maria Andrea Carranza (PIP 11220110101158) and the National Council of Science and Technology (CONACYT), grant Font. Inst./58/2016 to RH-P.